StockData

Lensar vs RxSight

LNSR and RXST side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LNSR and RXST compare

RxSight is the larger company, worth 3.3 times as much as Lensar ($201M against $60.3M).

Lensar grew revenue faster over the last twelve months (3.3% versus −13.2% for RxSight).

Lensar keeps more of each dollar of sales as profit, with a net margin of 57.6% compared with −36.8% at RxSight.

RxSight scores higher on the StockData Score (10 against 8 for Lensar), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLNSRRXST
Size and price
Market cap$60.3M$201M
Share price$4.91$4.83
Change, 1 year−51.4%−50.4%
Change, 5 years−30.0%−61.0%
Beta (5Y)1.611.33
Employees150461
StockData Score
Total score810 (better)
Valuation score23 (better)
Growth score22
Performance score2 (better)1
Health score24 (better)
Dividend score00
Valuation
P/S1.0× (better)1.6×
P/B4.0×0.8× (better)
FCF yield–−13.5%
Fair value$6.31$20.39
Margin of safety22.2%76.3% (better)
Growth
Revenue growth (TTM)3.3% (better)−13.2%
Revenue growth, 5Y average17.2%55.7% (better)
Profitability
Gross margin48.3%77.5% (better)
Operating margin−13.5% (better)−43.2%
Net margin57.6% (better)−36.8%
FCF margin–−21.3%
Return on equity–−17.3%
Return on invested capital–−82.9%
Financial health
Debt / equity0.25 (better)0.00
Interest coverage–−3674.3×
Current ratio2.394.07 (better)
Altman Z-score−0.93−0.70 (better)
Piotroski F-score33
Dividends and buybacks
Buyback yield–−1.00%
Shareholder yield0.00% (better)−1.00%
Ownership
Held by institutions36.0%99.6%
Held by insiders–5.4%
Insider net buying, 12 months–−$118K
Short interest, % of float–9.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.